Esperion Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ESPR and other ETFs, options, and stocks.

About ESPR

Esperion Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. 

CEO
Sheldon L. Koenig
CEOSheldon L. Koenig
Employees
294
Employees294
Headquarters
Ann Arbor, Michigan
HeadquartersAnn Arbor, Michigan
Founded
1998
Founded1998
Employees
294
Employees294

ESPR Key Statistics

Market cap
671.56M
Market cap671.56M
Price-Earnings ratio
-12.46
Price-Earnings ratio-12.46
Dividend yield
Dividend yield
Average volume
5.17M
Average volume5.17M
High today
$2.66
High today$2.66
Low today
$2.52
Low today$2.52
Open price
$2.55
Open price$2.55
Volume
5.85M
Volume5.85M
52 Week high
$4.18
52 Week high$4.18
52 Week low
$0.6925
52 Week low$0.6925

Stock Snapshot

With a market cap of 671.56M, Esperion Therapeutics(ESPR) trades at $2.66. The stock has a price-to-earnings ratio of -12.46.

As of 2026-04-03, Esperion Therapeutics(ESPR) stock has fluctuated between $2.52 and $2.66. The current price stands at $2.66, placing the stock +5.5% above today's low and -0.0% off the high.

The Esperion Therapeutics(ESPR)'s current trading volume is 5.85M, compared to an average daily volume of 5.17M.

In the last year, Esperion Therapeutics(ESPR) shares hit a 52-week high of $4.18 and a 52-week low of $0.69.

In the last year, Esperion Therapeutics(ESPR) shares hit a 52-week high of $4.18 and a 52-week low of $0.69.

ESPR News

TipRanks 12h
Esperion Completes Corstasis Acquisition, Expands Cardiovascular Portfolio

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...

TipRanks 14h
Esperion, Athyrium Capital enter $50M royalty financing agreement

Athyrium Capital and Esperion (ESPR) announced the entry into a $50M royalty financing agreement under which certain funds managed by Athyrium Capital Managemen...

TipRanks 3d
Esperion Therapeutics: CLEAR Outcomes Stroke Data and Commercial Momentum Underscore Buy-Rated Cardiovascular Franchise

Joseph Pantginis, an analyst from H.C. Wainwright, maintained the Buy rating on Esperion. The associated price target remains the same with $16.00. Unlock hedg...

Analyst ratings

71%

of 7 ratings
Buy
71.4%
Hold
14.3%
Sell
14.3%

More ESPR News

TipRanks 4d
Esperion showcases new data from CLEAR Outcomes trial

Esperion (ESPR) announced the presentation of two post-hoc analyses from the CLEAR Outcomes trial focused on the risk of ischemic stroke and major adverse cardi...

Nasdaq 7d
Karyopharm Therapeutics Stock Jumps 6.9%: Will It Continue to Soar?

Karyopharm Therapeutics (KPTI) shares ended the last trading session 6.9% higher at $5.57. The jump came on an impressive volume with a higher-than-average numb...

Karyopharm Therapeutics Stock Jumps 6.9%: Will It Continue to Soar?

People also own

Based on the portfolios of people who own ESPR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.